John Mascola
Specialist
Credentials: · ·
History
Infectious Disease
Internal Medicine
Research
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
New England Journal of Medicine · 2021 · 8,425 citations
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report
New England Journal of Medicine · 2020 · 2,556 citations
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Nature · 2021 · 1,817 citations
- JL
89 papers
70 papers · 4 as a fellow
- MC
46 papers
- NL
33 papers
29 papers
- LH
28 papers
- MG
28 papers
- MR
28 papers
Grants
- 2015–2019
CAPRISA HIV-1 Neutralizing Antibodies: Harnessing Ontogeny for Immunogen Design
National Institute of Allergy and Infectious Diseases · U01
PI · $874.5K · Wits Health Consortium (Pty), Ltd
National Institute of Allergy and Infectious Diseases · ZIA
Contact PI · $28.1M · National Institute of Allergy and Infectious Diseases
Pre-Clinical Vaccine Development for Emerging and Re-Emerging Infectious Diseases
National Institute of Allergy and Infectious Diseases · ZIC
Contact PI · $11.7M · National Institute of Allergy and Infectious Diseases
Modifications to Improve HIV Neutralizing Antibodies
National Institute of Allergy and Infectious Diseases · ZIA
Contact PI · $11M · National Institute of Allergy and Infectious Diseases